Orthodox medicine considers multiple sclerosis (MS) a chronic, inflammatory, and degenerative neurological illness with no cure or exact cause. However, over 300 research studies relevant to MS have been conducted looking into cannabis and cannabinoids for the symptomatic treatment of MS.
The CannaKeys multiple sclerosis treatment algorithm is based on review and analysis of scientific literature and clinical expert opinion. Focused on aspects that can be controlled in the clinical setting, it is designed to be used as a tool for creating optimal cannabinoid-based therapeutics for ms patients while managing the complexities of the endocannabinoid system.
If you are seeing this message, you are not a CannaKeys subscriber and can't download this cannabis treatment algorithm.
Learn more about our Chronic Pain Treatment Algorithm ebooks for Clinicians and Patients.
Or subscribe to CannaKeys.com to access all of our research dashboards and treatment algorithms.
Evidence-based Guidelines for Cannabis Therapeutics
We offer a systematic approach that physicians and healthcare professionals can use to make evidence-based decisions when prescribing cannabis or cannabinoids to treat multiple sclerosis pain and spasticity. Factors that can make a significant difference in optimizing patient outcomes include the choice of a primary cannabinoid, a secondary cannabinoid, and the ideal ratio between them, specific dosing protocols, forms, and additional synergy-inducing constituents.
Screening Process
Includes risk assessment, possible contraindications, and potential cannabinoid-to-pharmaceutical drug interactions.
Cannabinoid Treatment Plans
Dosing protocols consider patient preference regarding cognitive changes and altered states, and include starting dose, maximum daily dose, and titration rates for primary and secondary cannabinoids.
Cannabis-based Terpenes
Terpenes with therapeutic potential for the treatment of multiple sclerosis with links to clinical studies.
Nutraceuticals and Supplements
All relevant herbs and nutraceuticals that interact with the endocannabinoid system or the broader endocannabinoidome with clinical evidence for treating multiple sclerosis pain and spasticity.
Microbiome and Dietary considerations
All dietary considerations and food products that engage the microbiome and interact with the endocannabinoid system or the broader endocannabinoidome with clinical evidence for treating multiple sclerosis symptoms.
